now describe the ways of implementing the invention described herein with reference to the preferred embodiment using taxol as the anticancer agent acetyl l carnitine as the substantially protective agent and propionyl l carnitine as the substantially synergistic agent it remains understood that the expert in the field may complete the experimental protocols with his or her own general knowledge of the field in which he or she operates possibly resorting to neighbouring sectors in case of need we report here below the results of the most significant experiments suitable for demonstrating the unexpected and surprising protective effect obtained by the combination of l carnitine or its derivatives with the above mentioned anticancer agents the purpose of this experiment is to demonstrate and evaluate the protective effect expressed as an increase in survival time induced by l carnitine in a murine experimental model groups of 10 male wistar rats aged 3 months charles river were used housed at 22 u00b1 2 u00b0 c with 50 u00b1 15 relative humidity and a 12 hour light darkness cycle maintained with water and feed u201c ad libitum u201d the rats were treated with the anticancer agents intravenously i v at the doses corresponding to their respective ld 30 ld 50 and ld 80 the treatments with l carnitine 200 mg kg were administered subcutaneously once.